X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
MYLAN
Dec-18
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2783,412-   
Low Rs8831,878-   
Sales per share (Unadj.) Rs228.41,570.2-  
Earnings per share (Unadj.) Rs10.442.6-  
Cash flow per share (Unadj.) Rs16.3336.6-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.81,698.7-  
Shares outstanding (eoy) m25.00514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 280.8%   
Avg P/E ratio x104.262.0 168.0%  
P/CF ratio (eoy) x66.47.9 845.5%  
Price / Book Value ratio x10.91.6 702.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,361,038 2.0%   
No. of employees `0001.435.0 3.9%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.923,082.1 18.2%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1626.8 30.5%   
INCOME DATA
Net Sales Rs m5,710807,875 0.7%  
Other income Rs m1230-   
Total revenues Rs m5,833807,875 0.7%   
Gross profit Rs m463209,048 0.2%  
Depreciation Rs m147151,266 0.1%   
Interest Rs m038,856 0.0%   
Profit before tax Rs m43818,926 2.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-3,011 -5.9%   
Profit after tax Rs m25921,937 1.2%  
Gross profit margin %8.125.9 31.3%  
Effective tax rate %40.8-15.9 -256.7%   
Net profit margin %4.52.7 167.1%  
BALANCE SHEET DATA
Current assets Rs m3,209451,116 0.7%   
Current liabilities Rs m2,070328,914 0.6%   
Net working cap to sales %20.015.1 132.0%  
Current ratio x1.61.4 113.1%  
Inventory Days Days7284 86.6%  
Debtors Days Days3593 37.4%  
Net fixed assets Rs m790156,714 0.5%   
Share capital Rs m50430 11.6%   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,469873,973 0.3%   
Long term debt Rs m0943,297 0.0%   
Total assets Rs m4,6052,344,335 0.2%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 359.8%   
Return on assets %5.62.6 217.0%  
Return on equity %10.52.5 418.0%  
Return on capital %17.73.2 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88167,876 0.1%  
From Investments Rs m-94-86,774 0.1%  
From Financial Activity Rs mNA-78,207 0.0%  
Net Cashflow Rs m-61,391 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.69 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: CIPLA  WYETH LTD  STERLING BIOTECH  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation (The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead (The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound (Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now (Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks (The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - UNICHEM LAB COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS